REGENXBIO Inc.

Regenxbio Inc.

Biotechnology • Healthcare • Rockville, MD, United States • RGNX (NMS)

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase III clinical trial for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I, RGX-181 for the treatment of late-infantile neuronal ceroid lipofuscinosis type 2, and RGX-381 for the treatment of the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.

240 552 8181 9804 Medical Center Drive, Rockville, MD 20850, United States

Stock Performance (90 Days)

Data through Dec 26, 2025
Price updates on page refresh. Intraday quotes available during market hours (9:30 AM - 4:00 PM EST).

Layoff History

No layoff events recorded for this company.

Recent News

Stifel raises Regenxbio stock price target to $45 on upcoming catalysts - Investing.com
Investing.com • Dec 19
$RGNX stock is down 11% today. Here's what we see in our data. - Quiver Quantitative
Quiver Quantitative • Jan 2
REGENXBIO (NASDAQ:RGNX) Stock Price Up 5.2% - Time to Buy? - MarketBeat
MarketBeat • Dec 13
REGENXBIO’s Late-Stage Pipeline Momentum Strengthens After Q3 Earnings Beat (NASDAQ:RGNX) - Seeking Alpha
Seeking Alpha • Nov 8
Trading the Move, Not the Narrative: (RGNX) Edition - Stock Traders Daily
Stock Traders Daily • Jan 2

Other Biotechnology Companies

View All →
CODEXIS, INC. logo Codexis, Inc.
1 layoff tracked
$144.5M market cap
VERTEX PHARMACEUTICALS INC / MA logo Vertex Pharmaceuticals Inc. / MA
$118.68B market cap
REGENERON PHARMACEUTICALS, INC. logo Regeneron Pharmaceuticals, Inc.
$82.72B market cap
ALNYLAM PHARMACEUTICALS, INC. logo Alnylam Pharmaceuticals, Inc.
$52.92B market cap
ARGENX SE logo Argenx SE
$52.62B market cap
INSMED Inc logo Insmed Inc.
$37.61B market cap

Frequently Asked Questions

Has REGENXBIO Inc. had layoffs?
No layoff events have been recorded for REGENXBIO Inc. in our database. This could mean the company has not conducted significant layoffs, or any layoffs have not been publicly reported.
How many employees does REGENXBIO Inc. have?
REGENXBIO Inc. has approximately 353 employees.
What industry is REGENXBIO Inc. in?
REGENXBIO Inc. operates in the Biotechnology industry, within the Healthcare sector.
Is REGENXBIO Inc. a publicly traded company?
Yes, REGENXBIO Inc. is publicly traded under the ticker symbol RGNX on the NMS. The company has a market capitalization of approximately $0.72 billion.
Where is REGENXBIO Inc. headquartered?
REGENXBIO Inc. is headquartered in Rockville, MD, United States at 9804 Medical Center Drive, Rockville, MD 20850, United States.

Disclaimer

Data aggregated from public sources including WARN notices, SEC filings, press releases, and market data. While we strive for accuracy, information is provided "as-is" for informational purposes only. Always verify critical information with official company sources.

This information does not constitute investment, financial, legal, or career advice. See our Terms of Service, Privacy Policy, and About page for more information.

Found an error? Report it here.